Scientists affiliated with the University of Lethbridge have just released the results of some groundbreaking research that details how CBD aids in blocking the COVID-19 cells that enter the body in case of an infection. The study, published in the academic peer journal Preprints, was performed by a group of researchers in April of this year. The results were then published earlier this month, and the title of the preclinical study is In Search of Preventive Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues\u201d. This information was first made public in a statement by the pharmaceutical research company Pathway RX. The research is a collaboration between the university, Swysh Inc., a company that develops cannabis products for oral health and Pathway, which uses cannabis to treat various diseases. Scientists in Canada and Alberta performed a study with the aid of artificial 3D models of airway, intestinal, and oral tissues. These were coupled with a small sample of Cannabis sativa extracts rich in CBD, which modulate the ACE2 gene expression and the protein levels of ACE2. According to the study, hemp extracts containing a lot of CBD assist in blocking proteins that provide a certain \u201cgateway\u201d for the novel coronavirus to enter human cells. Dr. Igor Kovalchuk, CEO of the company Pathway Rx and a licensed Cannabis Researcher in Canada, said that ACE2 (Angiotensin-converting enzyme 2) is believed to be, in the scientific community, a receptor which SARRS-CoV-2 uses to enter human cells. He also mentioned that the initial findings require further investigation, but there is a significant chance that medical cannabis products could assist in the treatment of COVID-19. The results of the study were made public, and the research paper was also submitted to an academic journal so that it can be peer-reviewed.